Safety and immunogenicity of a heterologous prime-bosst vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in healthy adults, children and infants in a malaria endemic area.

Trial Profile

Safety and immunogenicity of a heterologous prime-bosst vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in healthy adults, children and infants in a malaria endemic area.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs ME-TRAP malaria DNA vaccine Okairos (Primary)
  • Indications Malaria
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Mar 2012 Planned end date (Mar 2011) added as reported by Pan-African Clinical Trials Registry record.
    • 20 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top